A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma

Despite emerging targeted and immunotherapy treatments, no monoclonal antibodies or antibody-drug conjugates (ADCs) directly targeting tumor cells are currently approved for melanoma therapy. The tumor-associated antigen chondroitin sulphate proteoglycan 4 (CSPG4), a neural crest glycoprotein over-e...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancers (Basel)
Main Authors: Hoffmann, Ricarda M., Crescioli, Silvia, Mele, Silvia, Sachouli, Eirini, Cheung, Anthony, Chui, Connie K., Andriollo, Paolo, Jackson, Paul J. M., Lacy, Katie E., Spicer, James F., Thurston, David E., Karagiannis, Sophia N.
Formato: Artigo
Idioma:Inglês
Publicado: MDPI 2020
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7226475/
https://ncbi.nlm.nih.gov/pubmed/32331483
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12041029
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares